Galderma SA, an R&D pharmaceutical company, has initiated clinical development of a novel
muscle relaxant, based on an advanced formulation of botulinum toxin, with the first cohort of patients already treated in the initial clinical study. "Muscle relaxants ...
[Published Individual.com - Jun 12 2013]